Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025 % ChangeQ4 2024 Full Year2025 % ChangeFull Year2024Revenue $748.2 2% $2,730.4 (8%)Gross profit $195.1 (11%) $774.1 (16%)Net income (loss) ($7.7) nm ($95.7) nmDiluted earnings (loss) per share ($0.20) nm ($2.48) nmAdjusted diluted EPS* $0.22 (70%) $1.36 (59%)Adjusted EBITDA* $54.5 (27%) $234.5 (31%)* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP...

STEINHAUSEN, Switzerland, Feb. 19, 2026 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) today reported financial results for the fourth quarter and full year of 2025. The Company will hold a conference call and webcast at 9 a.m. EST, 3 p.m. CET, on Friday, February 20, 2026, to discuss the results, with participation details included in this release. In addition, supplemental slides have been posted to the Investors section of the Company’s website at www.deepwater.com. 2025 KEY POINTSOperating revenues were $3.965 billion, up 13% from $3.524 billion in 2024. Revenue efficiency(1) was 96.5%, up from 94.5%. Net loss attributable to controlling interest was $2.915 billion, $3.04 per diluted share. Adjusted EBITDA of $1.37 billion, up from $1.148 billion or 19%. Cash flows from operations were $749 million, up $302 million or 68%. Free...

MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adjusted operating cash flowRevenue of US$803.8 million, up by 56%3 and achieving upsized full year guidance4. US$157.1 million invested in research and development (R&D) product development for late-stage therapeutics and precision medicine pipeline assets5, in line with stated FY 2025 guidance. Adjusted EBITDA6 of US$39.5 million, reflective of increased operating expenditure driven by strategic acquisitions, investment in commercial infrastructure and research and development (R&D). A non-material loss before tax...

MARKHAM, Ontario, Feb. 19, 2026 (GLOBE NEWSWIRE) — Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced its financial results for the three and twelve months ended December 31, 2025. HighlightsAverage Same Property Occupancy in retirement segment up 180 basis points (“bps”) year over year, to 94.7% in Q4 2025, further increasing to 95.2% in January 2026 Revenue exceeds $1.0 billion in 2025, up 15.0% year-over-year Same Property Net Operating Income (“NOI”), excluding One-Time Items, up 10.1% year-over-year to $47.4 million in Q4 2025Retirement Segment up 15.4% year-over-year in Q4 2025 Long-Term Care (“LTC”) Segment up 5.6% year-over year in Q4 2025Adjusted Funds from Operations (“AFFO”), excluding One-Time Items, increased by 19.8% year-over-year, or by 3.9% on a per share basis, in Q4 2025 AFFO...

 This news release contains forward-looking information about expected future events that is subject to risks and assumptions set out in the “Cautionary Statement on Forward-Looking Information” below. All figures are in United States dollars. All production figures reflect payable metal quantities and are on a 100% basis, unless otherwise stated. For references denoted with NG, refer to the “Non-GAAP and Other Financial Measures” disclosure at the end of this news release for a description of these measures. TORONTO, Feb. 19, 2026 (GLOBE NEWSWIRE) — Centerra Gold Inc. (“Centerra” or the “Company”) (TSX: CG and NYSE: CGAU) today reported its fourth quarter and full year 2025 operating and financial results and issued 2026 guidance. President and CEO, Paul Tomory, commented, “In the fourth quarter, we delivered strong production...

(All amounts expressed in U.S. dollars unless otherwise noted) VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (“Eldorado” or the “Company”) today reports the Company’s financial and operational results for the fourth quarter and year ended December 31, 2025. For further information please see the Company’s Consolidated Financial Statements and Management’s Discussion and Analysis (“MD&A”) filed on SEDAR+ at www.sedarplus.com under the Company’s profile. Q4 2025 and Full-Year Summary OperationsGold production: 123,416 ounces in Q4 2025. Full-year 2025 production of 488,268 ounces, achieving the higher-end of 2025 production guidance. Gold sales: 126,923 ounces in Q4 2025 at an average realized gold price per ounce sold(1) of $4,251, resulting in 491,204 ounces sold in 2025 at...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES (Note: All dollar amounts in this press release are expressed in U.S. dollars except as otherwise noted. The financial results are derived from unaudited financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS® Accounting Standards”), except as otherwise noted. This press release contains certain non-GAAP and other financial measures, including book value per share and cash and marketable securities, that do not have a prescribed meaning under IFRS Accounting Standards and may not be comparable to similar financial measures presented by other issuers. See “Glossary of non-GAAP and other financial measures” at...

(Note: All dollar amounts in this news release are expressed in U.S. dollars except as otherwise noted. The financial results are derived from unaudited consolidated financial statements prepared using the recognition and measurement requirements of International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS Accounting Standards”). This news release contains certain non-GAAP and other financial measures, including underwriting profit (loss), adjusted operating income (loss), gross premiums written, net premiums written, combined ratio (both discounted and undiscounted), float, book value per basic share, total debt to total capital ratio excluding non-insurance companies and excess (deficiency) of fair value over carrying value, that do not have a prescribed meaning under IFRS...

Diluted earnings per share (“EPS”) of $2.36 Invested $96 million in water and wastewater utility infrastructure during 2025, successfully delivering the planned 2025 capital investments Utility infrastructure investment of $506 million planned from 2026 through 2028 Constructive outcome of regulatory proceedings in New Jersey Declared $0.36 per share common stock dividendISELIN, N.J., Feb. 19, 2026 (GLOBE NEWSWIRE) — Middlesex Water Company (“Middlesex” or the “Company”) (NASDAQ: MSEX) today announced financial results for the fourth quarter and year end 2025. “We appreciate the diligence and commitment of the New Jersey Board of Public Utilities Staff and the Division of Rate Counsel throughout the review of our general rate case,” said Nadine Leslie, Chair, President and Chief Executive Officer of Middlesex Water Company....

Quarterly revenue of $748 million; GAAP loss of ($0.20)/share and adjusted EPS of $0.22 DALLAS, Feb. 19, 2026 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced its fourth quarter and full year 2025 financial results. Financial highlights are as follows: Dollars in millions, except per share amounts.  Q4 2025 % ChangeQ4 2024 Full Year2025 % ChangeFull Year2024Revenue $748.2 2% $2,730.4 (8%)Gross profit $195.1 (11%) $774.1 (16%)Net income (loss) ($7.7) nm ($95.7) nmDiluted earnings (loss) per share ($0.20) nm ($2.48) nmAdjusted diluted EPS* $0.22 (70%) $1.36 (59%)Adjusted EBITDA* $54.5 (27%) $234.5 (31%)* See “Non-GAAP Measures” below for a discussion of our use of non-GAAP...